Moses S Elisaf (Moses Elisaf)

Publication Activity (10 Years)

Years Active: 2017-2019
Publications (10 Years): 15

Top Topics

Chronic Kidney Disease

Insulin Resistance

Top Venues

Journal of cardiovascular pharmacology and therapeutics

Current medical research and opinion

Expert opinion on drug metabolism & toxicology

Postgraduate medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Kostas Archontogeorgis, Nikolaos Papanas, Evangelos C Rizos, Evangelia Nena, Athanasios Zissimopoulos, Christina Tsigalou, Athanasios Voulgaris, Dimitri P Mikhailidis, Moses S Elisaf, Marios E Froudarakis, Paschalis Steiropoulos
Reduced Serum Vitamin D Levels Are Associated with Insulin Resistance in Patients with Obstructive Sleep Apnea Syndrome. Medicina (Kaunas, Lithuania) 55 (5) (2019)
Eleni Pappa, Christos V Rizos, Theodosios D Filippatos, Moses S Elisaf
Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. Journal of cardiovascular pharmacology and therapeutics 24 (4) (2019)
Ioanna Papakitsou, George Vougiouklakis, Moses S Elisaf, Theodosios D Filippatos
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clinical pharmacology : advances and applications 11 (2019)
Theodosios D Filippatos, Thalia Panagiotopoulou, Eleftheria Tzavella, Moses S Elisaf
Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. Journal of cardiovascular pharmacology and therapeutics 23 (3) (2018)
Vasilis Tsimihodimos, Anastazia Kei, Fotini Apostolou, Moses S Elisaf
Diagnostic lipid changes in patients with visceral leishmaniasis. Hospital practice (1995) 46 (4) (2018)
Sempastian Filippas-Ntekouan, Vasilios Tsimihodimos, Theodosios D Filippatos, Theodora Dimitriou, Moses S Elisaf
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. Expert opinion on drug metabolism & toxicology 14 (11) (2018)
Theodosios D Filippatos, Moses S Elisaf, George Liamis
Pharmacological management of hyponatremia. Expert opinion on pharmacotherapy 19 (12) (2018)
Haralampos Milionis, Moses S Elisaf, Evangelos N Liberopoulos, Rigas Kalaitzidis, George Liamis
Uric acid and incident chronic kidney disease in dyslipidemic individuals. Current medical research and opinion 34 (7) (2017)
Anastazia Kei, Moses S Elisaf
Vorapaxar in secondary prevention: where we stand. Current medical research and opinion 33 (11) (2017)
Haralampos Milionis, Moses S Elisaf
National hyperlipidemia management policies improve lipid target attainment in clinical practice. Current medical research and opinion 34 (2) (2017)
Sebastian Filippas-Ntekouan, Theodosios D Filippatos, Moses S Elisaf
SGLT2 inhibitors: are they safe? Postgraduate medicine 130 (1) (2017)
Theodosios D Filippatos, Anastazia Kei, Moses S Elisaf
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? Diseases (Basel, Switzerland) 5 (4) (2017)
Theodosios D Filippatos, Eleftheria Tzavella, Christos V Rizos, Moses S Elisaf, George Liamis
Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert opinion on drug safety 16 (10) (2017)
Theodosios D Filippatos, Anastazia Kei, Christos V Rizos, Moses S Elisaf
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. Journal of cardiovascular pharmacology and therapeutics 23 (1) (2017)
Christos V Rizos, Theodosios D Filippatos, Moses S Elisaf
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Expert opinion on drug metabolism & toxicology 14 (1) (2017)